Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

Rizos, Emmanouil; Papadopoulou, Aikaterini; Laskos, E.; Michalopoulou, Panayiota G.; Kastania, Athanasia; Vasilopoulos, Dimitrios; Katsafouros, Konstantinos; Lykouras, Lefteris

doi:10.1080/15622970802182733

Cited by 33 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, decreases in BDNF have already been detected in different psychotic disorders (Buckley et al, 2007;Chen da et al, 2009;Rizos et al, 2008;Sen et al, 2008), including BD (Kapczinski et al, 2008). In addition, a decrease in BDNF expression has been observed in many animal models of stress (Smith et al, 1995;Nibuya et al, 1995;Roceri et al, 2002;Tsankova et al, 2007).…”

Section: Dna Methylation Of Bdnf Gene In Bipolar Disorder C D'addariomentioning

confidence: 99%

Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII

D’Addario

Dell’Osso

Palazzo

et al. 2012

Neuropsychopharmacol

160

107

View full text Add to dashboard Cite

The etiology of bipolar disorder (BD) is still poorly understood, involving genetic and epigenetic mechanisms as well as environmental contributions. This study aimed to investigate the degree of DNA methylation at the promoter region of the brain-derived neurotrophic factor (BDNF) gene, as one of the candidate genes associated with major psychoses, in peripheral blood mononuclear cells isolated from 94 patients with BD (BD I ¼ 49, BD II ¼ 45) and 52 healthy controls. A significant BDNF gene expression downregulation was observed in BD II 0.53±0.11%; Po0.05), but not in BD I (1.13±0.19%) patients compared with controls (CONT: 1±0.2%). Consistently, an hypermethylation of the BDNF promoter region was specifically found in BD II patients (CONT: 24.0±2.1%; BDI: 20.4±1.7%; BDII: 33.3 ± 3.5%, Po0.05). Of note, higher levels of DNA methylation were observed in BD subjects on pharmacological treatment with mood stabilizers plus antidepressants (34.6 ± 4.2%, predominantly BD II) compared with those exclusively on mood-stabilizing agents (21.7 ± 1.8%; Po0.01, predominantly BD I). Moreover, among the different pharmacological therapies, lithium (20.1 ± 3.8%, Po0.05) and valproate (23.6 ± 2.9%, Po0.05) were associated with a significant reduction of DNA methylation compared with other drugs (35.6 ± 4.6%). Present findings suggest selective changes in DNA methylation of BDNF promoter in subjects with BD type II and highlight the importance of epigenetic factors in mediating the onset and/or susceptibility to BD, providing new insight into the mechanisms of gene expression. Moreover, they shed light on possible mechanisms of action of mood-stabilizing compounds vs antidepressants in the treatment of BD, pointing out that BDNF regulation might be a key target for their effects.

show abstract

Section: Dna Methylation Of Bdnf Gene In Bipolar Disorder C D'addariomentioning

confidence: 99%

Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII

D’Addario

Dell’Osso

Palazzo

et al. 2012

Neuropsychopharmacol

160

107

View full text Add to dashboard Cite

show abstract

“…Despite a host of existing trials addressing the effects of pharmacological interventions (PIs) on peripheral BDNF levels in schizophrenia, while discrepant findings have been observed both in serum and plasma levels of BDNF [41][42][43][44][45][46][47][48], few studies have examined the association between NPIs and peripheral BDNF levels in patients with schizophrenia, and the results of studies have been discordant. This meta-analysis included six RCTs with 289 participants in total.…”

Section: Discussionmentioning

confidence: 99%

“…A reduction in peripheral BDNF levels has been reported in patients with schizophrenia compared to healthy controls [31,41,44,55,56], including medication naïve and first-episode schizophrenia patients [12,43,[57][58][59][60]. However, a few studies reported increased serum BDNF levels [61,62] or no significant differences in serum BDNF levels [63,64].…”

Section: Discussionmentioning

confidence: 99%

The efficacy of non-pharmacological interventions on brain-derived neurotrophic factor in schizophrenia: a systematic review and meta-analysis

Sanada¹,

Zorrilla²,

Bermúdez-Ampudia³

et al. 2016

European Neuropsychopharmacology

View full text Add to dashboard Cite

“…In the medical literature, there are some studies that demonstrate that the serum BDNF levels in schizophrenic patients are lower than those in healthy controls [3,20,21] but some studies demonstrate higher serum BDNF levels in schizophrenic patients than in healthy controls [12,22]. There are many studies that demonstrate that patients with MDD have lower levels of serum BDNF than do control patients [4,7,23].…”

Section: Discussionmentioning

confidence: 99%

Prediction of Depression in Schizophrenia: Can serum Levels of BDNF or EGF Help us?

Yavaşcı¹

2014

J Psychiatry

View full text Add to dashboard Cite

show abstract

Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

Cited by 33 publications

References 0 publications

Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII

Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII

The efficacy of non-pharmacological interventions on brain-derived neurotrophic factor in schizophrenia: a systematic review and meta-analysis

Prediction of Depression in Schizophrenia: Can serum Levels of BDNF or EGF Help us?

Contact Info

Product

Resources

About